Business
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
Health economics and outcomes research showed post-Stupp therapeutic developments, including TTFields, significantly increase overall survival in a large
About this update from Novocure Limited
[{"type":"text","content":"\nHealth economics and outcomes research showed post-Stupp therapeutic developments, including TTFields, significantly increase overall survival in a large commercially insured population\n\nThe largest safety dataset to date of more than 23,000 patients reinforced that TTFields therapy is well-tolerated in patients with high-grade gliomas\n\n ROOT, Switzerland--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) today announced 25 abstracts on Tumor Treating Fields (TTFields) therapy will be featured at the Society for Neuro-Oncology (SNO) 2022 Annual Meeting from Nov. 16 to Nov. 20 in Tampa. The presentations cover a broad range of topics, including TTFields’ multimodal mechanism of action, safety and tolerability, and health economics and outcomes research (HEOR).\n\nNew research in HEOR includes an analysis by a coalition of researchers at Central Brain Tumor Registry of the United States (CBTRUS), Duke University and the National Cancer Institute that utilized commercial claims and population-based datasets to better understand potential treatment factors associated with improved survival for glioblastoma (GBM) (Corey Neff, M.P.H., Department of Neurosurgery, Duke University School of Medicine in Durham, North Carolina, et al.) The presentation, “Improvements in survival for glioblastoma in the post-Stupp protocol era,” showed that survival in GBM has continued to improve over time in the post-Stupp protocol era, which may be due to developments of new therapeutic approaches. The analysis showed post-Stupp therapeutic developments, including TTFields, significantly increase overall survival in the commercially insured population. Of the 19,414 identified adult patients with GBM, 3,061 used TTFields therapy. These patients experienced an extended median overall survival compared to patients who were not treated with TTFields (17.6 months versus 13.1 months, respectively; hazard ratio: 0.77; P","length":2372,"tagName":"div"}]